179 related articles for article (PubMed ID: 22443102)
1. Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis.
Barrière G; Riouallon A; Renaudie J; Tartary M; Rigaud M
BMC Cancer; 2012 Mar; 12():114. PubMed ID: 22443102
[TBL] [Abstract][Full Text] [Related]
2. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P
Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334
[TBL] [Abstract][Full Text] [Related]
5. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.
Aktas B; Tewes M; Fehm T; Hauch S; Kimmig R; Kasimir-Bauer S
Breast Cancer Res; 2009; 11(4):R46. PubMed ID: 19589136
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
Bredemeier M; Kasimir-Bauer S; Kolberg HC; Herold T; Synoracki S; Hauch S; Edimiris P; Bankfalvi A; Tewes M; Kimmig R; Aktas B
Mol Med Rep; 2017 May; 15(5):2957-2968. PubMed ID: 28358430
[TBL] [Abstract][Full Text] [Related]
7. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
8. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
[TBL] [Abstract][Full Text] [Related]
10. TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-β1.
Kim YH; Kim G; Kwon CI; Kim JW; Park PW; Hahm KB
Oncol Rep; 2014 Mar; 31(3):1380-8. PubMed ID: 24402192
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor.
Ito M; Shien T; Omori M; Mizoo T; Iwamoto T; Nogami T; Motoki T; Taira N; Doihara H; Miyoshi S
Breast Cancer; 2016 May; 23(3):437-44. PubMed ID: 25599843
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of Stemlike Circulating Tumor Cells in Invasive Breast Cancer.
Savelieva OE; Tashireva LA; Kaigorodova EV; Buzenkova AV; Mukhamedzhanov RK; Grigoryeva ES; Zavyalova MV; Tarabanovskaya NA; Cherdyntseva NV; Perelmuter VM
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316333
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
14. LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells.
Trapp EK; Majunke L; Zill B; Sommer H; Andergassen U; Koch J; Harbeck N; Mahner S; Friedl TWP; Janni W; Rack B; Alunni-Fabbroni M
Mol Oncol; 2017 Nov; 11(11):1508-1526. PubMed ID: 28700115
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of
Strati A; Nikolaou M; Georgoulias V; Lianidou ES
Cells; 2019 Jun; 8(7):. PubMed ID: 31261917
[TBL] [Abstract][Full Text] [Related]
17. Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.
Krawczyk N; Meier-Stiegen F; Banys M; Neubauer H; Ruckhaeberle E; Fehm T
Biomed Res Int; 2014; 2014():415721. PubMed ID: 24895575
[TBL] [Abstract][Full Text] [Related]
18. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer.
Bonnomet A; Syne L; Brysse A; Feyereisen E; Thompson EW; Noël A; Foidart JM; Birembaut P; Polette M; Gilles C
Oncogene; 2012 Aug; 31(33):3741-53. PubMed ID: 22120722
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
Mego M; Karaba M; Minarik G; Benca J; Silvia J; Sedlackova T; Manasova D; Kalavska K; Pindak D; Cristofanilli M; Reuben JM; Mardiak J
Anticancer Res; 2019 Apr; 39(4):1829-1837. PubMed ID: 30952723
[TBL] [Abstract][Full Text] [Related]
20. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
